Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.
2.

Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.

Rojas LE, Herrero MJ, Bosó V, García-Eliz M, Poveda JL, Librero J, Aliño SF.

Pharmacogenet Genomics. 2013 Oct;23(10):509-17. doi: 10.1097/FPC.0b013e3283642fb3. Review.

PMID:
23873120
3.

Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.

Uesugi M, Kikuchi M, Shinke H, Omura T, Yonezawa A, Matsubara K, Fujimoto Y, Okamoto S, Kaido T, Uemoto S, Masuda S.

Pharmacogenet Genomics. 2014 Jul;24(7):356-66. doi: 10.1097/FPC.0000000000000060.

PMID:
24911663
4.

Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.

Argudo A, González de Aledo JM, Alía P, Ramírez P, Serrano T, Fabregat J, Castellote J.

Transplant Proc. 2015 Oct;47(8):2388-92. doi: 10.1016/j.transproceed.2015.09.024.

PMID:
26518936
5.

Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.

Buendía JA, Otamendi E, Kravetz MC, Cairo F, Ruf A, de Davila M, Powazniak Y, Nafissi J, Lazarowski A, Bramuglia G, Villamil F.

Exp Clin Transplant. 2015 Oct;13(5):441-8.

6.

Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.

Uesugi M, Hosokawa M, Shinke H, Hashimoto E, Takahashi T, Kawai T, Matsubara K, Ogawa K, Fujimoto Y, Okamoto S, Kaido T, Uemoto S, Masuda S.

Biol Pharm Bull. 2013;36(11):1814-21.

7.

Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.

Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M.

Transplantation. 2012 Nov 27;94(10):1013-9. doi: 10.1097/TP.0b013e31826bc400.

PMID:
23073468
8.

Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.

Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, Latinne D, Wallemacq P, Mourad M, Haufroid V.

Ther Drug Monit. 2013 Oct;35(5):608-16. doi: 10.1097/FTD.0b013e318296045b.

PMID:
24052064
9.

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Staatz CE, Goodman LK, Tett SE.

Clin Pharmacokinet. 2010 Mar;49(3):141-75. doi: 10.2165/11317350-000000000-00000. Review.

PMID:
20170205
10.

Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.

Ji E, Choi L, Suh KS, Cho JY, Han N, Oh JM.

Transplantation. 2012 Oct 27;94(8):866-72. doi: 10.1097/TP.0b013e318263700a.

11.

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.

Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, Xi LY, Cheng K, Ming YZ, Yang GP, Pei Q, Zhu LJ, Yuan H, Liao HQ, Ding JJ, Wu D, Zhou YN, Jing NN, Huang ZJ.

Pharmacogenet Genomics. 2013 May;23(5):251-61. doi: 10.1097/FPC.0b013e32835fcbb6.

PMID:
23459029
12.

Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients.

Gómez-Bravo MA, Salcedo M, Fondevila C, Suarez F, Castellote J, Rufian S, Pons JA, Alamo JM, Millán O, Brunet M.

J Clin Pharmacol. 2013 Nov;53(11):1146-54. doi: 10.1002/jcph.154.

PMID:
23900887
13.

Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.

Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L.

Gene. 2013 Jan 10;512(2):226-31. doi: 10.1016/j.gene.2012.10.048.

PMID:
23107770
14.

CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.

Glowacki F, Lionet A, Buob D, Labalette M, Allorge D, Provôt F, Hazzan M, Noël C, Broly F, Cauffiez C.

Nephrol Dial Transplant. 2011 Sep;26(9):3046-50. doi: 10.1093/ndt/gfr253.

15.

Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.

Tang HL, Xie HG, Yao Y, Hu YF.

Pharmacogenet Genomics. 2011 Nov;21(11):713-20. doi: 10.1097/FPC.0b013e32834a48ca.

PMID:
21886016
16.

Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.

Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K.

Pharmacogenet Genomics. 2008 May;18(5):413-23. doi: 10.1097/FPC.0b013e3282f9ac01.

PMID:
18408564
17.

Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.

Rahsaz M, Azarpira N, Nikeghbalian S, Aghdaie MH, Geramizadeh B, Moini M, Banihashemi M, Darai M, Malekpour Z, Malekhosseini SA.

Exp Clin Transplant. 2012 Feb;10(1):24-9.

18.

Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.

Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Gridelli B, D'Alessandro N.

Int J Mol Med. 2011 Dec;28(6):1093-102. doi: 10.3892/ijmm.2011.794.

PMID:
21922127
19.

Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.

Miura M, Satoh S, Kagaya H, Saito M, Numakura K, Tsuchiya N, Habuchi T.

Pharmacogenomics. 2011 Jul;12(7):977-84. doi: 10.2217/pgs.11.33.

PMID:
21635144
20.

Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation.

Wang Z, Wu S, Chen D, Guo F, Zhong L, Fan J, Peng Z.

Eur J Clin Pharmacol. 2014 Aug;70(8):925-31. doi: 10.1007/s00228-014-1673-2.

PMID:
24820765
Items per page

Supplemental Content

Support Center